Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
Faculty Arvind Dasari, MD, MS
Professor
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Van K Morris, MD
Associate Professor Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jenny Seligmann, MBChB, PhD
Professor of Gastrointestinal Cancer
University of Leeds
Leeds, United Kingdom
Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospitals Leuven
Leuven, Belgium
Moderator Christopher Lieu, MD
Professor of Medicine
Associate Director for Clinical Research
Co-Director, GI Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado
This activity is supported by educational grants from GSK, Natera Inc, and Pfizer Inc.
MODULE 1: Optimizing Biomarker Assessment for Patients with Colorectal Cancer (CRC) — Dr Dasari
Prevalence, prognostic relevance and therapeutic implications of validated biomarkers of treatment response in patients with CRC, such as RAS mutations, microsatellite instability (MSI)/mismatch repair (MMR) deficiency, HER2 overexpression and BRAF V600E mutations
Appropriate timing of biomarker assessment; role in localized versus newly diagnosed metastatic versus relapsed/refractory disease
Benefits and limitations of available assays and testing platforms for biomarker analysis
Rationale for the use of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) monitoring in CRC; published datasets evaluating the use of ctDNA testing
Ongoing studies examining the utility of ctDNA-based MRD testing in guiding treatment decision-making and monitoring for recurrence; potential clinical impact
MODULE 2: Identification and Management of Metastatic CRC (mCRC) with a BRAF V600E Mutation — Dr Morris
Long-term findings from the Phase III BEACON CRC study of encorafenib/cetuximab with or without binimetinib for patients with mCRC and BRAF V600E mutations
Appropriate integration of encorafenib/cetuximab into therapy for BRAF V600E-mutated mCRC
Rationale for the evaluation of earlier use of BRAF-targeted therapy; findings from the Phase II ANCHOR CRC trial evaluating encorafenib/binimetinib/cetuximab for treatment-naïve patients with BRAF V600E-mutated mCRC
Recent FDA approval of encorafenib in combination with cetuximab and chemotherapy as first-line treatment for BRAF V600E-mutated mCRC based on the results of the Phase III BREAKWATER trial
Early results with and ongoing evaluation of BRAF-targeted therapy in combination with anti-PD-1/PD-L1 antibodies for MSI-high (MSI-H)/MMR-deficient (dMMR) and microsatellite-stable/MMR-proficient mCRC
MODULE 3: Incorporation of Immune Checkpoint Inhibitors into the Management of MSI-H/dMMR CRC — Dr Seligmann
Early data with neoadjuvant immune checkpoint inhibitors for patients with resectable nonmetastatic MSI-H/dMMR CRC
Updated results with dostarlimab as an alternative to surgery for MSI-H/dMMR locally advanced rectal cancer; FDA breakthrough therapy designation for this strategy
Ongoing studies, such as AZUR-1 and AZUR-2, evaluating dostarlimab in lieu of surgery or administered perioperatively for patients with resectable MSI-H/dMMR tumors
Long-term results from the Phase III KEYNOTE-177 study evaluating front-line pembrolizumab versus chemotherapy for newly diagnosed MSI-H/dMMR mCRC
Key efficacy and safety findings from the Phase III CheckMate 8HW trial evaluating nivolumab/ipilimumab versus chemotherapy for previously untreated MSI-H/dMMR mCRC
MODULE 4: Integration of Therapies Targeting HER2 into the Management of mCRC — Prof Van Cutsem
Published data from the pivotal Phase II MOUNTAINEER trial evaluating tucatinib/trastuzumab for previously treated HER2-positive mCRC
FDA approval of tucatinib/trastuzumab and optimal incorporation into the mCRC treatment paradigm
Available efficacy and safety findings (eg, from the DESTINY-CRC01 and DESTINY-CRC02 trials) with trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing mCRC
FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for mCRC management
Spectrum, incidence and severity of adverse events with tucatinib/trastuzumab and with T-DXd in patients with mCRC; optimal approaches to monitoring and management
MODULE 5: Biomarker-Based Decision-Making for Patients with mCRC and KRAS G12C Mutations — Dr Lieu
Rationale for the historical perception of KRAS as an “undruggable” target in advanced cancer
Available data with sotorasib and adagrasib monotherapy for mCRC
Mechanistic justification for combining KRAS G12C inhibitors with EGFR antibodies for mCRC
Published findings with sotorasib/panitumumab and adagrasib/cetuximab for previously treated KRAS G12C-mutated mCRC
Recent FDA approval and current clinical role of adagrasib/cetuximab for KRAS G12C-mutated mCRC
Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer (CRC).
Learning Objectives
Upon completion of this activity, participants should be able to
Develop an understanding of validated biomarkers of response in CRC, such as RAS mutations, microsatellite instability (MSI)/mismatch repair (MMR) deficiency, HER2 overexpression and BRAF V600E mutations, and consider the implications for molecular testing and clinical care.
Optimize the use of neoadjuvant and adjuvant systemic therapy for patients with localized CRC, considering various clinical and biological factors such as age, performance status, disease stage, MSI/MMR status and the potential relevance of molecular residual disease.
Formulate a plan to guide the selection and sequencing of therapy for patients with metastatic CRC (mCRC), accounting for tumor sidedness, biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
Evaluate the biological rationale for the use of immune checkpoint inhibitors in the treatment of MSI-high/MMR-deficient localized or advanced CRC, and counsel patients regarding evidence-based and guideline-endorsed therapy recommendations.
Appreciate published and emerging research documenting the efficacy of BRAF/EGFR inhibition for newly diagnosed or relapsed/refractory mCRC with a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into patient care.
Recognize available data with HER2-targeted therapies for HER2-positive mCRC, and consider the current role of FDA-approved approaches.
Apply available research to optimize the selection and sequencing of therapy for patients with mCRC and a KRAS G12C mutation, considering the implications of recent clinical trial findings and regulatory actions.
Recall ongoing trials evaluating novel biomarker-directed agents and strategies for CRC, and use this information to appropriately refer patients for study participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
MODERATOR
— Dr Lieu — Consulting Agreements: Amgen Inc, Pfizer Inc; Contracted Research: Genentech, a member of the Roche Group, Sanofi.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from GSK, Natera Inc, and Pfizer Inc.
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600
Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2025 ASCO® Gastrointestinal Cancers Symposium is taking place.
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ASCO Gastrointestinal Cancers Symposium.
IN-PERSON registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2025 ASCO® Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
